Related Experiment Video

Updated: Jun 22, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Follicular thyroid cancer cell growth inhibition by proteosome inhibitor MG132

Samantha J Stoll1, Susan C Pitt, Herbert Chen

  • 1Endocrine Surgery Research Laboratory, Department of Surgery, University of Wisconsin, Madison, WI 53792-3284, USA.

The Journal of Surgical Research
|June 26, 2009
PubMed
Abstract

Insights

Proteasome inhibition effectively suppressed growth in metastatic follicular thyroid cancer (FTC) cells. This approach, using MG132, shows promise as a novel therapeutic strategy for aggressive FTC, warranting further investigation into its mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Metastatic follicular thyroid cancer (FTC) presents a significant therapeutic challenge due to a lack of effective treatments.
  • Proteasome inhibitors represent an emerging class of chemotherapeutic agents with potential applications in oncology.

Purpose of the Study:

  • To investigate the efficacy of proteasome inhibition using MG132 on metastatic human FTC cells (FTC236).
  • To elucidate the molecular mechanisms underlying the anti-proliferative effects of proteasome inhibition in FTC.

Main Methods:

  • In vitro treatment of FTC236 cells with varying concentrations of the proteasome inhibitor MG132.
  • Western blot analysis to assess protein expression changes (GSK-3beta, beta-catenin, p21, cyclin D1).
  • MTT assay to quantify cellular proliferation over a 6-day period.

Main Results:

  • MG132 demonstrated dose-dependent inhibition of FTC236 cell growth, with an 87% reduction at 800 nM (P < 0.0001).
  • Observed increases in phosphorylated GSK-3beta and active beta-catenin suggest pathway modulation.
  • MG132 treatment led to increased p21(Waf1/Cip1) and decreased cyclin D1, indicating potential cell cycle arrest.

Conclusions:

  • Proteasome inhibition effectively suppresses the growth of metastatic human FTC cells.
  • The findings suggest that proteasome inhibitors may serve as novel therapeutic agents for aggressive, metastatic FTC.
  • Further research is needed to confirm the direct role of cell cycle arrest and GSK-3beta signaling inactivation.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...